Central serotonergic activity measured by citalopram challenge test and platelet monoamine oxidase activity, associations with gene polymorphism (5-HTTLPR) and impulsivity

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-005103-16-EE

Enrollment

Registered

2005-02-09

Start date

2005-02-09

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

Trade Name: Cipramil Product Name: Cipramil Product Code: R Pharmaceutical Form: Coated tablet INN or Proposed INN: citalopram Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy men and women, aged 20-55, volunteers, nonsmokers Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: any mental or physical illnesses

Design outcomes

Primary

Measure	Time frame
Main Objective: Assessing central serotonergic activity by citalopram challenge test;Secondary Objective: ;Primary end point(s): prolactin level in venous blood	—

Countries

Estonia

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026